Captivate® is the clinical research platform from Captivate, Inc., built to accelerate the design, launch, and execution of modern trials. Positioned as the leading AI platform for clinical research, Captivate brings together eClinical software, secure infrastructure, and expert services so sponsors, CROs, and researchers can move from protocol to database lock faster—without compromising quality or compliance.
Our mission is simple: build software that saves lives by helping life-changing therapies reach patients sooner.
Orphan diseases affect millions worldwide but often receive little attention because of limited financial incentives for drug development.
By removing the software cost barrier, Weidley’s Wish empowers nonprofits, academic researchers, and small organizations to run clinical trials that would otherwise be impossible.
This initiative not only accelerates rare disease research but also strengthens global collaboration, giving investigators in under-resourced regions the same technology used by leading pharmaceutical companies.
– Khaled Prince, Head of Clinical Operations, ClinMax
At the height of the pandemic, Captivate expanded Weidley’s Wish to include free EDC access for COVID-19 treatment and vaccine trials. Organizations like ClinMax leveraged Captivate® to launch multiple national studies in Egypt, reporting a 40% faster build time compared to legacy EDCs and praising Captivate®’s ease of use, advanced features, and responsive support.
As the need for affordable, compliant software grew, Weidley’s Wish evolved again to include startups, small sponsors, and nonprofits requiring prevalidated, full-featured EDC systems without the budget for traditional commercial platforms. Unlike other “freemium” vendor models, Weidley’s Wish participants receive access to the same powerful tools used by global sponsors.
“Weidley’s Wish gave us access to enterprise-grade EDC software that would have been impossible to afford otherwise. This has been transformative for our rare disease research.”
Dr. Rachel Martinez
Principal Investigator, Rare Disease Research Foundation
“What Captivate is doing is outstanding and has an impact on the world. The platform helped us launch our COVID-19 vaccine trial 40% faster than expected.”
Khaled Prince
Head of Clinical Operations, ClinMax
“The support from Captivate through Weidley’s Wish has allowed our small nonprofit to conduct critical orphan drug trials that will benefit thousands of patients globally.”
Dr. James Chen
Research Director, Global Health Initiative
Company News
January 15, 2025
Captivate announces a major expansion of its Weidley’s Wish program, providing enterprise-grade EDC software to qualifying research organizations worldwide. The initiative now serves over 50 organizations across 20 countries, accelerating critical research in rare diseases and orphan drug development.
Case Study
November 8, 2024
Leading clinical research organization ClinMax leverages Captivate’s EDC platform through Weidley’s Wish to launch multiple COVID-19 vaccine trials across Egypt. The team reported significantly faster build times and praised the platform’s ease of use and advanced features compared to legacy systems.
Partnership
September 22, 2024
A nonprofit research organization successfully completes FDA submission for a rare disease treatment trial, powered by Captivate’s validated EDC system provided through Weidley’s Wish. This marks a significant milestone in making advanced clinical trial technology accessible to under-resourced research teams.
If you’re part of a nonprofit, startup, or small research team working on a study that aligns with the mission of Weidley’s Wish—especially in underserved areas like rare diseases, orphan drug development, or global health—we invite you to apply.
Eligible organizations receive access to Captivate®’s fully-featured, validated EDC system with special discounts applied. Apply here and someone from the Captivate team will reach out to you.
